Century Therapeutics Secures $135 Million Private Placement to Advance iPSC-Derived Cell Therapy for Type 1 Diabetes
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) —
Century Therapeutics (NASDAQ: IPSC), a pioneer in induced pluripotent stem cell (iPSC)-derived therapies, announced today that it has signed a securities purchase agreement for a private placement expected to yield initial gross proceeds of approximately $135 million.
The financing, led by new investor TCGX with participation from heavyweights like RA Capital Management and Venrock, significantly strengthens the company’s balance sheet. If all warrants are fully exercised, Century could gain an additional $153 million, bringing the total potential proceeds to nearly $288 million.
Funding a Potential Cure for Type 1 Diabetes
The primary driver behind this capital infusion is CNTY-813, Century’s lead product candidate. CNTY-813 is an iPSC-derived beta islet cell program designed as a potentially curative treatment for Type 1 diabetes (T1D).
“We believe this financing enables our ambition to unlock the full potential of CNTY-813,” said Brent Pfeiffenberger, Pharm.D., CEO of Century Therapeutics. “We are grateful for the high level of conviction shown by top investors focused on high-impact diseases.”
Extended Runway and Key Milestones
The financing provides Century with a robust financial cushion, extending its cash runway into Q1 2029. This timeline allows the company to reach several critical clinical inflection points:
-
2026: Anticipated Investigational New Drug (IND) submission for CNTY-813.
-
2027: Expected release of initial clinical data.
Transaction Details
Under the agreement, Century will issue over 117 million shares of common stock (or pre-funded warrants) at a price of $1.15 per share. The accompanying warrants carry an exercise price of $2.60 and are set to expire either three years from closing or 30 days following the public announcement of Phase 1 clinical data for CNTY-813.
The offering, managed by placement agents Leerink Partners, TD Cowen, and Mizuho, is expected to close on January 9, 2026.
Source:
https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-secures-oversubscribed-135-million-private
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related Services
-
Custom mRNA Service
- High-quality mRNA with full QC panel
- Custom scales, stability, and modifications
- End-to-end support from design to manufacturing
-
Custom mRNA-LNP Service
- Increased stability with protected mRNA delivery
- Enhanced uptake via optimized LNP formulations
- Reduced immunogenicity for safer applications
-
Fast mRNA Service for Gene Editing
- Cas9, Nickase, Cre, and more for gene editing
- Fast, on-demand delivery for urgent projects
- N1-methyl-pseudo Uridine to reduce immune response
